Genomic Health, Inc. (NASDAQ:GHDX) insider Kimberly J. Popovits sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, August 14th. The stock was sold at an average price of $30.22, for a total transaction of $151,100.00. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Kimberly J. Popovits also recently made the following trade(s):

  • On Wednesday, July 5th, Kimberly J. Popovits sold 1,468 shares of Genomic Health stock. The stock was sold at an average price of $32.67, for a total transaction of $47,959.56.
  • On Wednesday, July 5th, Kimberly J. Popovits sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $32.59, for a total transaction of $162,950.00.
  • On Monday, June 5th, Kimberly J. Popovits sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $32.32, for a total transaction of $161,600.00.

Shares of Genomic Health, Inc. (GHDX) traded down 0.30% during trading on Wednesday, reaching $30.32. 88,359 shares of the company traded hands. Genomic Health, Inc. has a 12-month low of $25.66 and a 12-month high of $33.97. The firm’s 50-day moving average is $32.02 and its 200-day moving average is $31.24. The stock’s market capitalization is $1.05 billion.

Genomic Health (NASDAQ:GHDX) last announced its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.06) by $0.02. The business had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The company’s revenue was up 4.3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.18) earnings per share. On average, equities analysts predict that Genomic Health, Inc. will post $0.01 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/16/kimberly-j-popovits-sells-5000-shares-of-genomic-health-inc-ghdx-stock.html.

A number of analysts have recently weighed in on the stock. Canaccord Genuity cut their price target on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating for the company in a report on Tuesday. BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies reissued a “hold” rating and issued a $31.00 price objective on shares of Genomic Health in a research note on Thursday, August 3rd. Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Finally, Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price objective on shares of Genomic Health in a research note on Monday, June 12th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $32.00.

Large investors have recently made changes to their positions in the company. Dubuque Bank & Trust Co. acquired a new stake in shares of Genomic Health during the first quarter worth $142,000. Norges Bank acquired a new stake in shares of Genomic Health during the fourth quarter worth $4,546,000. American International Group Inc. raised its stake in shares of Genomic Health by 7.1% in the first quarter. American International Group Inc. now owns 11,505 shares of the medical research company’s stock worth $362,000 after buying an additional 765 shares during the last quarter. Teachers Advisors LLC raised its stake in shares of Genomic Health by 6.1% in the fourth quarter. Teachers Advisors LLC now owns 31,801 shares of the medical research company’s stock worth $935,000 after buying an additional 1,838 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. raised its stake in shares of Genomic Health by 8.6% in the first quarter. Schwab Charles Investment Management Inc. now owns 482,675 shares of the medical research company’s stock worth $15,200,000 after buying an additional 38,199 shares during the last quarter. Hedge funds and other institutional investors own 88.54% of the company’s stock.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.